Get started
Author

Peter J. King

Observed names: Peter J King, Peter King
Observed institution: Immuneering (United States)
ORCID: 0009-0004-9395-9014
Observed ORCID: 0009-0004-9395-9014
OpenAlex ID: A5064638147
377 Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the pulsatile MEK inhibitor, atebimetinib, enhances PD-1 checkpoint blockade in RAS mutant tumors
2026 · Amy E Axel, Amy Yamamura, et al. · Journal for ImmunoTherapy of Cancer
PDF
Supplementary Table S4 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Table S3 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Figure S3 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Data from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 6 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Figure S2 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 4 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Table S1 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Table S2 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 5 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Table 1 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 3 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Figure S1 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS - and RAF -Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al. · Cancer Research
Abstract B021: Pan-RAS IMM-1-104 activity in humanized 3D tumor models is independent of specific amino acid substitution
2023 · Sarah Kolitz, Praveen Nair, et al. · Molecular Cancer Research
Abstract 4265: Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors
2023 · Praveen Nair, Sarah Kolitz, et al. · Cancer Research
Works count: 17
Citation count:
H-index:
I10-index:
Year
Topic
Type